Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Replay Of Avandia Ban, Saudi Arabia First Regulator To Withdraw Long-acting Beta Agonists As Sole Therapy

This article was originally published in PharmAsia News

Executive Summary

The Saudi Arabia Food and Drug Authority appears to be the first regulatory agency to announce a withdrawal of long acting beta agonists that are not combined with corticosteroids, citing evidence of a linkage to an increased risk of death from asthma-related complications
Advertisement

Related Content

Korea FDA Withdraws Abbott's Meridia; Criticism Increases On Agency's Dependence On U.S. FDA For Safety
Saudi Regulators Suspend Use Of Avandia; GSK Says Action Not Based On Recent Data
Saudi Regulators Suspend Use Of Avandia; GSK Says Action Not Based On Recent Data
FDA Calls For Class-Wide REMS For LABA Asthma Drugs
Advertisement
UsernamePublicRestriction

Register

SC073911

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel